Biotheryx’s Initial Alliance Pairs With Incyte On Targeted Protein Degradation

 
• By Joseph Haas

Biotheryx will deploy its PRODEGY platform to discover candidates against novel cancer targets selected by Incyte. The deal occurred the same day as a Merck/Proxygen protein-degradation alliance.

Cancer researchers
Biotheryx and Incyte will team up to research novel cancer targets • Source: Shutterstock

More from Deals

More from Business